SCHEMBL24256970

SCHEMBL24256970

CCCc1nc2sc3c(NCCc4c[nH]c5ccccc45)ncnc3c2c2c1CCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.47
KDM4E B2RXH2 5/20 0.47
MAPT P10636 3/20 0.47
MAPK1 P28482 3/20 0.47
RAD52 P43351 3/20 0.47
IDE P14735 1/20 0.47
UBE2N P61088 1/20 0.47
LMNA P02545 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GFER P55789 1/20 0.45
PDPK1 O15530 1/20 0.45
RPS6KB1 P23443 1/20 0.45
ABCC1 P33527 1/20 0.45
POLB P06746 5/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 2/20 0.44
TSHR P16473 2/20 0.44
APOBEC3A P31941 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256611 0.83 MAPT (0.36) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256614 0.80 HTT (0.55) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256699 0.77 KDM4E (0.49) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256695 0.77 KDM4E (0.53) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256352 0.77 POLB (0.51) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256693 0.76 KDM4E (0.46) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256356 0.75 NPC1 (0.48) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256613 0.75 RAD52 (0.47) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256346 0.75 ALDH1A1 (0.67) HTTKDM4EMAPTMAPK1RAD52
SCHEMBL24256706 0.74 NPC1 (0.49) HTTKDM4EMAPTMAPK1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 HTT 2169/4885KDM4E 1927/4885MAPT 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.